StreetInsider.com News Articles

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in a pivotal study evaluating IBI363 (Takeda R&D code: TAK-928), a potential first-in-class PD-1/IL-2^α-biased bispecific fusion protein, in combination with bevacizumab versus investigator's choice of therapy, in patients with advanced colorectal cancer (CRC) that is refractory or intolerant to

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Wed, 05 Aug 2026 20:00:00 -0400

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Sc

Mon, 13 Jul 2026 08:00:00 -0400

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the